Miller, Schuman receive ARVO/Pfizer Ophthalmics award

October 24, 2005

Rockville, Md. -- The Association for Research in Vision and Ophthalmology (ARVO) announced today that Joan W. Miller, MD, and Joel S. Schuman, MD, have been selected to receive the 2006 ARVO/Pfizer Ophthalmics Translational Research Award during ARVO's Annual Meeting to be held in Fort Lauderdale, Fla., in May 2006.

The ARVO/Pfizer Award is presented to honor excellence in research and fundamental scientific discoveries, concepts and novel technologies, leading to clinical evidence of diagnosis, prevention, or amelioration of the pathological eye and/or an understanding of the normal vision processes. The award is presented to two researchers annually.

Miller was selected for her research in non-human primates, and subsequent translation to humans, leading to the development of photodynamic therapy of neovascular age-related macular degeneration. She is the Henry Willard Williams Professor and Chair of Ophthalmology at Harvard Medical School. In addition, Miller is Chief of Ophthalmology at the Massachusetts Eye and Ear Infirmary in Boston. She is a past recipient of the American Academy of Ophthalmology Achievement Award, the Alcon Research Institute Award, and the Retina Research Award of the Club Jules Gonin. Miller is the Chairman of the Executive Committee of the Harvard Medical School Department of Ophthalmology.

Schuman was chosen for his role as a key researcher in the development of optical coherence tomography that is widely used clinically in the diagnosis and management of glaucoma and retinal diseases. He is Eye and Ear Foundation Professor and Chairman of Ophthalmology at the University of Pittsburgh School of Medicine. In 2002, Schuman received the Alcon Research Institute Award of Excellence and, the following year, the American Academy of Ophthalmology's Senior Achievement Award. He serves on numerous editorial boards for vision-related journals including Investigative Ophthalmology & Visual Science and Glaucoma Today, and is also a member of the Executive Committee of the University of Pittsburgh School of Medicine.
Established in 1928, ARVO is a membership organization of more than 11,300 eye and vision researchers from over 70 countries. The Association encourages and assists its members and others in research, training, publication, and dissemination of knowledge in vision and ophthalmology. ARVO's headquarters are located in Rockville, Md. For more information about ARVO, logon to the Association's Web site,

Association for Research in Vision and Ophthalmology

Related Glaucoma Articles from Brightsurf:

Monitoring glaucoma at home
Glaucoma is a chronic condition that affects cells at the back of the eye.

Study finds novel mechanism that may confer protection against glaucoma
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.

AI-supported test for very early signs of glaucoma progression
A new test can detect glaucoma progression 18 months earlier than the current gold standard method, according to results from a UCL-sponsored clinical trial.

New method gives glaucoma researchers control over eye pressure
Neuroscientists have developed a new method that permits continuous regulation of eye pressure without damage, becoming the first to definitively prove pressure in the eye is sufficient to cause and explain glaucoma.

Glaucoma care in prison inmates
Data fromĀ 82 prison inmates treated in a glaucoma clinic at an academic hospital were used in this observational study to report on how treatment and follow-up, including medication adherence, were are managed.

New glaucoma test to help prevent blindness
Researchers have identified 107 genes that increase a person's risk of developing the eye disease glaucoma, and now developed a genetic test to detect those at risk of going blind from it.

Air pollution linked to higher glaucoma risk
Living in a more polluted area is associated with a greater likelihood of having glaucoma, a debilitating eye condition that can cause blindness, finds a new UCL-led study in the UK.

Long-term statin use associated with lower glaucoma risk
A new study brings the connection between statin use and risk of glaucoma into sharper focus.

Health burden of glaucoma has risen worldwide
The health burden of glaucoma has continuously increased around the globe in the past 25 years, according to an Acta Opthalmologica study.

UAlberta scientists first to pinpoint a cause of pigmentary glaucoma
An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition.

Read More: Glaucoma News and Glaucoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to